Edgewise Therapeutics reports positive Phase 2 heart data

• Edgewise Therapeutics announced positive 12-week Phase 2 trial results for its hypertrophic cardiomyopathy drug.
• The company's share price increased to $38.09 following the publication of the clinical data.
• The positive results support the company's planned initiation of a Phase 3 study in late 2026.

Edgewise Therapeutics (NASDAQ:EWTX) reported positive 12-week Phase 2 data evaluating its investigational heart disease treatment called EDG-7500.

The clinical trial results showed key improvements in heart performance metrics compared against standard historical baselines.

Patients in the CIRRUS-HCM study experienced functional improvements without showing drops in left ventricular ejection fraction below 50%.

The therapeutic candidate was generally well-tolerated by participants suffering from both obstructive and nonobstructive hypertrophic cardiomyopathy.

Following the announcement, Edgewise Therapeutics' share price was up at $38.09.

The medical milestone supports the company's broader corporate strategy to initiate a Phase 3 trial in late 2026.

The business recently executed a $2.65 billion agreement to sell its muscular dystrophy portfolio to expand its clinical resources.